Morgan Stanley and Jefferies Financial Group raised their ratings and price objectives for PTC Therapeutics.
5 reports, 2 independent
Updated Oct 13
Gone quiet
- Reports
- 5
- Developments
- 2
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley and Jefferies Financial Group raised their ratings and price objectives for PTC Therapeutics.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Cantor Fitzgerald and RBC issued new price target updates for PTC Therapeutics.1 source
Morgan Stanley and Jefferies upgraded PTC Therapeutics' rating and price objective.1 source
Keep exploring
The entities involved
-
PTC Therapeutics
pharmaceutical company
Nothing else this week.
-
Morgan Stanley
U.S. investment bank
-
Jefferies Financial Group
American financial services company
Related events
- Multiple financial firms, including Jefferies, Bank of America, and Raymond James, issued price objective and rating updates on October 23, 2026.
- Jefferies Financial Group began coverage, Morgan Stanley set a high price target, and Keefe, Bruyette & Woods increased price objectives, with MarketBeat reporting the average stock rating.
- Morgan Stanley and Jefferies Financial Group adjusted price targets and ratings for Lincoln National Corporation.
- Financial firms, including Jefferies, RBC, and Wells Fargo, issued rating and price objective updates for Biogen.
- Jefferies Financial Group initiated coverage on Moody's shares, and Morgan Stanley subsequently raised its price target for the company.